Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Liver Diseases

  Free Subscription


Articles published in Dig Dis

Retrieve available abstracts of 38 articles:
HTML format



Single Articles


    May 2022
  1. CAO D, Liu H, Bai L, Tang H, et al
    EMT-Related Gene Signature: A New Method for Personalized Risk Assessment in Patients with Hepatocellular Carcinoma.
    Dig Dis. 2022 May 30. pii: 000525232. doi: 10.1159/000525232.
    PubMed     Abstract available


    April 2022
  2. OP DEN WINKEL M, Nagel D, Seidensticker M, De Toni EN, et al
    Development and external validation of the Munich Sorafenib Evaluation Score for hepatocellular carcinoma.
    Dig Dis. 2022 Apr 14. pii: 000524336. doi: 10.1159/000524336.
    PubMed     Abstract available


    March 2022
  3. INUKAI Y, Yamamoto K, Honda T, Ito T, et al
    Differences in the intestinal microbiome associated with diarrhea during lenvatinib treatment for hepatocellular carcinoma.
    Dig Dis. 2022 Mar 28. pii: 000524298. doi: 10.1159/000524298.
    PubMed     Abstract available


  4. SHI L, Zhang S
    Identification of subclasses of decompensated cirrhotic patients with acute kidney injury with different responses to fluid input.
    Dig Dis. 2022 Mar 17. pii: 000524028. doi: 10.1159/000524028.
    PubMed     Abstract available


    February 2022
  5. JAHN M, Raschidi L, Ozcurumez MK, Arzideh F, et al
    Comparison of Mortality Prediction Scores in Intermediate-Care Patients with Liver Cirrhosis at a German university transplant Center; a prospective study.
    Dig Dis. 2022 Feb 16. pii: 000522595. doi: 10.1159/000522595.
    PubMed     Abstract available


  6. YAN J, Deng M, Wang Y, Zhu M, et al
    Transjugular intrahepatic portosystemic shunt for portal vein cavernous transformation: a systematic review and single-arm meta-analysis.
    Dig Dis. 2022 Feb 7. pii: 000522313. doi: 10.1159/000522313.
    PubMed     Abstract available


    January 2022
  7. MIJAC D, Krstic MN, Markovic AP, Popovic DD, et al
    Abnormal Liver Blood Tests: Primary Care Approach.
    Dig Dis. 2022;40:215-222.
    PubMed     Abstract available


  8. SEHGAL R, Kaur N, Ramakrishna G, Trehanpati N, et al
    Immune Surveillance by Myeloid-Derived Suppressor Cells in Liver Diseases.
    Dig Dis. 2022;40:301-312.
    PubMed     Abstract available


    November 2021
  9. SHAO X, Uojima H, Arai T, Ogawa Y, et al
    The risk of cirrhosis and its complications based on PNPLA3 rs738409 G allele frequency.
    Dig Dis. 2021 Nov 22. pii: 000521062. doi: 10.1159/000521062.
    PubMed     Abstract available


  10. CHEN LS, Lee SW, Yang SS, Tsai HJ, et al
    Advances in the era of direct-acting antivirals for hepatitis C in patients with unresectable hepatocellular carcinoma.
    Dig Dis. 2021 Nov 9. pii: 000520721. doi: 10.1159/000520721.
    PubMed     Abstract available


  11. DREWES R, Heinze C, Pech M, Powerski M, et al
    Apparent diffusion coefficient can predict therapy response of hepatocellular carcinoma to transcatheter arterial chemoembolization.
    Dig Dis. 2021 Nov 8. pii: 000520716. doi: 10.1159/000520716.
    PubMed     Abstract available


    October 2021
  12. REITER FP, Ben Khaled N, Ye L, Zhang C, et al
    Advances in Pharmacotherapy of Hepatocellular Carcinoma: A State of the Art Review.
    Dig Dis. 2021 Oct 13. pii: 000520095. doi: 10.1159/000520095.
    PubMed    


    July 2021
  13. OSWALD L, Nakanishi H, Kurosaki M, Kirino S, et al
    Plasma renin activity predicts prognosis and liver disease-related events in liver cirrhosis patients with ascites treated by tolvaptan.
    Dig Dis. 2021 Jul 30. pii: 000518099. doi: 10.1159/000518099.
    PubMed    


    June 2021
  14. OCAL O, Rossler D, Ricke J, Seidensticker M, et al
    Advances in Diagnostic and Interventional Radiology in Hepatocellular Carcinoma.
    Dig Dis. 2021 Jun 29. pii: 000518101. doi: 10.1159/000518101.
    PubMed    


  15. KUBOTA K, Uojima H, Shao X, Iwasaki S, et al
    Additional L-carnitine Reduced the Risk of Hospitalization in Patients with Overt Hepatic Encephalopathy on Rifaximin.
    Dig Dis. 2021 Jun 28. pii: 000518067. doi: 10.1159/000518067.
    PubMed    


  16. OP DEN WINKEL M, Nagel D, de la Torre Alaez MA, Hempe S, et al
    A simple prognostic scoring system for hepatocellular carcinoma treated with selective internal radiation therapy.
    Dig Dis. 2021 Jun 10. pii: 000517458. doi: 10.1159/000517458.
    PubMed    


    May 2021
  17. KRSTIC MN, Mijac D, Tomasevic RS, Lukic S, et al
    Abnormal liver blood tests: Hepatologist approach.
    Dig Dis. 2021 May 10. pii: 000517110. doi: 10.1159/000517110.
    PubMed    


    April 2021
  18. MEYER JJ, Dreyhaupt J, Schwerdel D, Ettrich TJ, et al
    Blood-based targeted metabolomics discriminate patients with alcoholic liver cirrhosis from those with non-cirrhotic liver damage: an explorative study.
    Dig Dis. 2021 Apr 16. pii: 000516488. doi: 10.1159/000516488.
    PubMed    


  19. MANZHALII E, Falalyeyeva TM, Moyseyenko VO, Weiskirchen R, et al
    Elevation of autoantibodies to cerebral proteins in hepatic encephalopathy: Another pathogenic factor?
    Dig Dis. 2021 Apr 9. pii: 000516412. doi: 10.1159/000516412.
    PubMed     Abstract available


    January 2021
  20. KUSNIK A, Hunter N, Rasbach E, Miethke T, et al
    Co-Medication and nutrition in HCC: Potentially preventative strategies in Hepatocellular carcinoma (HCC).
    Dig Dis. 2021 Jan 11. pii: 000514277. doi: 10.1159/000514277.
    PubMed     Abstract available


  21. ANASTASIOU OE, Korth J, Herbstreit F, Witzke O, et al
    Mild versus Severe Liver Injury in SARS-CoV-2 Infection.
    Dig Dis. 2021;39:52-57.
    PubMed     Abstract available


  22. WEBER S, Benesic A, Buchholtz ML, Rotter I, et al
    Antimitochondrial Rather than Antinuclear Antibodies Correlate with Severe Drug-Induced Liver Injury.
    Dig Dis. 2021;39:275-282.
    PubMed     Abstract available


  23. XU Y, Hu X, Li J, Dong R, et al
    An Improved Scoring System Based on Platelet-Albumin-Bilirubin in Predicting Posthepatectomy Liver Failure Outcomes.
    Dig Dis. 2021;39:258-265.
    PubMed     Abstract available


  24. WADA N, Uojima H, Satoh T, Okina S, et al
    Impact of Anti-GPIIb/IIIa Antibody-Producing B Cells as a Predictor of the Response to Lusutrombopag in Thrombocytopenic Patients with Liver Disease.
    Dig Dis. 2021;39:234-242.
    PubMed     Abstract available


  25. PARK J, Lee EY, Li J, Jun MJ, et al
    NASH/Liver Fibrosis Prevalence and Incidence of Nonliver Comorbidities among People with NAFLD and Incidence of NAFLD by Metabolic Comorbidities: Lessons from South Korea.
    Dig Dis. 2021;39:634-645.
    PubMed     Abstract available


  26. YAMAMOTO K, Ikeya T, Okuyama S, Fukuda K, et al
    Association between the Frequency of Daily Toothbrushing and Development of Nonalcoholic Fatty Liver Disease.
    Dig Dis. 2021;39:646-652.
    PubMed     Abstract available


  27. FREITAS M, Macedo Silva V, Xavier S, Magalhaes J, et al
    Early Kidney Dysfunction in Metabolic-Associated Fatty Liver Disease: Is Transient Elastography Useful as a Screening Method?
    Dig Dis. 2021;39:653-662.
    PubMed     Abstract available


  28. ATTA S, Kamel M, Mansour W, Hussein T, et al
    Ascitic Fluid Cytokines in Chronic Liver Disease: A Possible Prognostic Tool.
    Dig Dis. 2021;39:534-539.
    PubMed     Abstract available


    November 2020
  29. IDILMAN R, Aydogan M, Oruncu MB, Kartal A, et al
    NATURAL HISTORY OF CIRRHOSIS: CHANGING TRENDS IN ETIOLOGY OVER THE YEARS.
    Dig Dis. 2020 Nov 3. pii: 000512746. doi: 10.1159/000512746.
    PubMed     Abstract available


  30. SCHINDLER P, Masthoff M, Harders F, Schmidt H, et al
    EFFICACY OF 90Y-RADIOEMBOLIZATION IN METASTATIC COLORECTAL CANCER DEPENDING ON THE PRIMARY TUMOR SIDE.
    Dig Dis. 2020 Nov 3. pii: 000512744. doi: 10.1159/000512744.
    PubMed     Abstract available


    September 2020
  31. BARABAS L, Hritz I, Istvan G, Tulassay Z, et al
    The behavior of MMP-2, MMP-7, MMP-9 and their inhibitors TIMP-1, TIMP-2 in adenoma-colorectal cancer sequence.
    Dig Dis. 2020 Sep 22. pii: 000511765. doi: 10.1159/000511765.
    PubMed     Abstract available


    August 2020
  32. MOON AM, Watkins SE, Lok AS, Firpi-Morell RJ, et al
    Opioid Use is More Common in Non-Alcoholic Fatty Liver Disease Patients with Cirrhosis, Higher Body Mass Index and Psychiatric Disease.
    Dig Dis. 2020 Aug 24. pii: 000511074. doi: 10.1159/000511074.
    PubMed     Abstract available


  33. RAMRAKHIANI NS, Le M, Yeo YH, Le A, et al
    Validity of International Classification of Diseases, 10th Revision, Codes for Cirrhosis.
    Dig Dis. 2020 Aug 19. pii: 000510981. doi: 10.1159/000510981.
    PubMed     Abstract available


    May 2020
  34. KIMURA N, Tsuchiya A, Oda C, Kimura A, et al
    Visceral adipose tissue index and hepatocellular carcinoma are independent predictors of outcome in patients with cirrhosis having endoscopic treatment for esophageal varices.
    Dig Dis. 2020 May 25. pii: 000508867. doi: 10.1159/000508867.
    PubMed     Abstract available


    March 2020
  35. MILOVANOVIC T, Popovic D, Stojkovic Lalosevic M, Dumic I, et al
    Quality Of Life in Patients With Primary Biliary Cholangitis: A Single Center Experience in Serbia.
    Dig Dis. 2020 Mar 6. pii: 000506980. doi: 10.1159/000506980.
    PubMed     Abstract available


  36. KANG MK, Kim KO, Kim MC, Park JG, et al
    Sarcopenia is a new risk factor of non-alcoholic fatty liver disease in patients with inflammatory bowel disease.
    Dig Dis. 2020 Mar 5. pii: 000506938. doi: 10.1159/000506938.
    PubMed     Abstract available


    January 2020
  37. DITE P, Blaho M, Bojkova M, Jabandziev P, et al
    Nonalcoholic Fatty Pancreas Disease: Clinical Consequences.
    Dig Dis. 2020;38:143-149.
    PubMed     Abstract available


  38. BLACKETT JW, Verna EC, Lebwohl B
    Increased Prevalence of Colorectal Adenomas in Patients with Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study.
    Dig Dis. 2020;38:222-230.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: